Skip to main
KYTX
KYTX logo

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics Inc is making significant strides in the development of cell therapies targeting autoimmune diseases, with positive preliminary results from its KYV-101 treatment demonstrating notable improvements in various patient mobility metrics, including QMG and MG-ADL scores. The company has also reported encouraging outcomes in multiple sclerosis, with patients showing substantial reductions in oligoclonal bands, suggesting a potential decrease in disease progression. Additionally, the prospect of expanding its treatment platform with KYV-201 for multiple autoimmune diseases speaks to the long-term growth potential of Kyverna's innovative therapeutic approach.

Bears say

Kyverna Therapeutics reported a net loss of $0.80 per share for the third quarter of 2024, with projections indicating a full-year loss of $3.14 per share, underscoring significant financial challenges. The company’s clinical results for KYV-101, particularly in lupus nephritis, have been disappointing, raising concerns about the efficacy of DNA-based CAR-T therapies and their ability to achieve durable responses in autoimmune diseases. Additionally, the competitive landscape in multiple sclerosis presents further challenges, as patients have access to a variety of existing treatments, making it difficult for Kyverna's products to gain traction in the market.

KYTX has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 5 analysts, KYTX has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.